P.P.M. Kooij's research while affiliated with Erasmus MC and other places

... Studies have shown that grade 3/4 hematologic toxicity in patients receiving PRRT has been in the acceptable range and patients with baseline poor renal function are more prone to this (18). As such, the incidence of PRRT-induced nephrotoxicity is low (19). ...

... For the dosimetric calculations in our study, the data were corrected only for the longer half-life of 177 Lu. On the basis of studies that directly compared the biodistribution characteristics of peptides functionalized with different chelators and labeled with various isotopes, we know that both the chelator (32)(33)(34) and the radiolabel (34,35) can influence the receptor affinity and biodistribution features of the tracer, as may explain the differences between the findings reported in the two studies. However, since our preclinical studies demonstrate that the use of chelators such as DTPA and DOTA, a potential chelator for 177 Lu (36), does not affect the biodistribution of exendin, we assumed similar biodistribution characteristics between DOTA-and DTPA-exendin tracers in humans. ...

... Conversely, liquid plugs can be used for therapeutic purpose [128,69]: boluses of surfactant are injected inside the lungs of prematurely born infants to compensate for their lack and improve ventilation [67,129]. A thorough understanding of liquid plugs dynamics is therefore mandatory to improve both treatments of patients suffering from obstructive pulmonary diseases and of prematurely born infants. ...

... To reduce radiation exposure to the most critical organ, that is, the kidney, several regimens of amino acid coinfusion have been tested by different groups (9,13,16,(22)(23)(24). In one study, infusion of mixed amino acids (120 g containing 26.4 g L-lysine ϩ L-argi-nine, i.e., 2 L Hartmann-HEPA 8%) over 4 h starting 30 min before radiotracer injection reduced the kidney uptake at all time points (22). ...

... [ 111 In-diethylenetriaminepentaacetic acid (DTPA)]-octreotide was the first analog used (2)(3)(4)(5)(6), followed by [ 90 Ydodecanetetraacetic acid (DOTA), Tyr 3 ]octreotide ( 90 Y-DOTATOC) (3,(7)(8)(9)(10)(11)(12)(13), [ 90 Y-DOTA]-lanreotide (14,15), and [ 177 Lu-DOTA, Tyr 3 ]octreotate (16). ...

... Studies have shown that grade 3/4 hematologic toxicity in patients receiving PRRT has been in the acceptable range and patients with baseline poor renal function are more prone to this (18). As such, the incidence of PRRT-induced nephrotoxicity is low (19). ...

... Two patients developed delayed-onset minimal-change nephrotic syndrome from 14 to 27 months after the last dose of 177 Lu-dotatate. A slow persistent decline in the creatinine clearance of a median of 3.8% per year has been reported with 177 Lu-dotatate PRRT though up to 5% of patients have an accelerated decline of >15% per year [13]. Further studies are needed to understand the mechanism underlying this toxicity. ...

... The Wistar rats (n = 3/time point) were sacrificed at designated time intervals post-injection (2 h, 24 h and 48 h), and the organs of interest were removed. The percentage of the injected dose per whole organ (% ID/organ) and percentage of the injected dose per gram of tissue (% ID/g) were determined using NaI (Tl) gamma counter [28,29]. ...

... Однако внедрение в практику данных радиофармацевтических агентов было затруднено из-за сложности радиометрии в экспериментальных условиях: вопросы радиометрии на фантомных моделях были разработаны только в 2015 году Brolin G. et al. (2015) [11]. 177 Lu-DOTA-TATE был сразу синтезирован в начале 2000-х годов как соединение с направленной доставкой к клеткам, высоко экспрессирующим рецепторы соматостатина, в частности, рецепторы второго типа -SSTR2 [12][13][14][15][16]. ...

... In the course of this work, we understood synthesis and biological evaluation of a novel 99m Tc-based somatostatin analog 3 with potential use in the visualization of SSTRpositive tumors. Though several somatostatin analogs labeled with a wide spectrum of radionuclides have already been reported (Lewis et al. 1999; Bakker et al. 1991) and an established radiopharmaceutical [ 111 In] OctreoScan is available (Krenning et al. 1992; de Jong et al. 1998), the search for a 99m Tc-somatostatin radiotracer has intensified (Bangard et al. 2000; Thakur et al. 1997; Weiner and Thakur 2002) due to the superior nuclear properties of 99m Tc and its cost effectiveness (Liu et al. 1997; Liu and Edwards 1999). Previous efforts to develop such an agent have mainly utilized octreotide/[Tyr 3 ] octreotide as the SSTR recognition site. ...